While there is some concern for off-tumor toxicity against normal myeloid-lineage cells, anti-FRβ CAR T-cells have been reported to have mild cytotoxic efficacy in vitro against FRβ-expressing AML cell lines with minimal toxicity against normal CD34+ HSCs (56). The gene discussed is FOLR2; the disease is neoplasm.